Caris Life Sciences Biomarker Research Suggests Role for Immune-targeted Therapies in Subsets of Patients with Triple Negative Breast Cancer (TNBC) - WRCBtv.com | Chattanooga News, Weather & Sports

Caris Life Sciences Biomarker Research Suggests Role for Immune-targeted Therapies in Subsets of Patients with Triple Negative Breast Cancer (TNBC)

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Caris Life Sciences

Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence™

CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of data identifying multiple novel biomarkers as potential targets for immunotherapeutic agents in triple negative breast cancer (TNBC), an aggressive form of breast cancer in which the cancer cells lack estrogen receptors (ER), progesterone receptors (PR), and large amounts of the HER2/neu protein. This oral presentation, presented at the 50th annual meeting of ASCO, was performed as sponsored research at Mayo Clinic in Phoenix, Ariz., utilizing Caris Molecular Intelligence™, Caris' comprehensive tumor profiling service.

In the study, researchers analyzed 511 TNBC samples to examine the biomarkers involved in immune evasion as potential therapeutic targets, with particular focus on programmed death ligand 1 (PD-L1) and its association with other biological pathways. Their multiplatform approach included whole genome messenger RNA (mRNA) expression, protein expression via immunohistochemistry (IHC), gene copy number changes via in situ hybridization (ISH), and gene sequencing. Thirty six of the samples were validated using the IHC platform. This research revealed how expression of immune regulatory targets in the TNBC population suggests that immune-targeted therapies may be effective in certain patients. Their findings are considered especially timely, given the growing interest in immunotherapy as a potential treatment option in TNBC and other tumor types.

"Targeted treatment options for triple negative breast cancer have historically been quite limited," said lead investigator Barbara Pockaj, M.D., at the Mayo Clinic in Phoenix, Ariz. "While the results need further investigation, they illustrate how use of multiplatform molecular profiling technologies can identify novel biomarkers as potential immunotherapeutic targets in TNBC and other difficult-to-treat cancers."

Several highlights from this clinical study include previously unreported findings in TNBC:

  • Patients with quadruple negative breast cancer (i.e., lacking the AR protein as well as ER, PR and HER-2) may benefit from immunotherapeutic agents
  • An inverse correlation between PD-L1 and BRCA1 indicates select TNBC patients may benefit from a combination of immunotherapy and platinum agents or PARP inhibitors
  • In particular, patients with androgen receptor (AR)-negative TNBC may benefit from therapies designed to inhibit the activity of molecules such as PD-L1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and indoleamine 2,3-dioxygenase 1 (IDO-1)

"This dataset underscores the importance of our partnership with the prestigious Mayo Clinic, as it illustrates how a comprehensive approach to molecular profiling can enhance the accuracy and specificity of tumor characterization in individual patients with triple negative breast cancer, potentially facilitating therapeutic decision-making," noted Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. "Caris is now examining PD-1 and PD-L1 in a broad variety of tumor types to better identify patients subsets that are likely to respond to this new class of therapy, which is being featured so highly at ASCO this year. Ongoing research of the biomarkers identified in this study will help further elucidate their associations with response to specific agents, possibly leading to improved treatment outcomes for patients with TNBC and other types of cancer."

About Caris Molecular Intelligence

Caris Molecular Intelligence™, the industry's leading cancer molecular profiling service, helps oncologists treat cancer smarter by delivering the most potential treatment options for patients. This service has been used by more than 6,000 oncologists to develop individualized and actionable treatment plans for more than 60,000 cancer patients in 59 countries across the globe. Caris Molecular Intelligence integrates the latest relevant panomics data - the combination of genes, proteins, molecular pathways, and unique patient characteristics - from clinical studies in cancer and cancer biology to identify the most clinically actionable drug associations approved by the U.S. Food & Drug Administration or in active clinical trials in the United States. Beyond standard DNA analysis, Caris Molecular Intelligence assesses all relevant biological components, such as RNA, protein expression and gene amplification levels, to provide oncologists with the most treatment options for their patients. Currently, Caris can identify therapeutic guidance for up to 51 drug associations, far exceeding the 19 that can be identified using next-generation sequencing alone. This therapeutic guidance is electronically delivered to the ordering physician in an easy-to-read report that enables development of tailored treatment plans. For more information on Caris Molecular Intelligence, visit www.carismolecularintelligence.com.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry's first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient's cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.

 

 

 

©2012 PR Newswire. All Rights Reserved.

  • NewsMore>>

  • Tony Stewart back at the track, looking to heal

    Tony Stewart back at the track, looking to heal

    Saturday, August 30 2014 12:20 AM EDT2014-08-30 04:20:07 GMT
    Tony Stewart should be back in his comfort zone at a NASCAR track, ready for racing.More
    Tony Stewart took his seat on the podium - unshaven, his eyes glassy - and unfolded a sheet of paper. His voice quivered as he read, pausing to maintain his composure as he described the death of a driver he hit as "one of...More
  • Grundy Co. Yellow Jackets Marching Band

    Grundy Co. Yellow Jackets Marching Band

    Friday, August 29 2014 11:34 PM EDT2014-08-30 03:34:57 GMT
    The Grundy County High School Band's Director says, "for a little band, they can make a good bit of noise!" To Yellow Jackets faithful and band aficionados, it is sweet music. They serenade us with Rocky Top and are our Band of the Week!More
    The Grundy County High School Band's Director says, "for a little band, they can make a good bit of noise!" To Yellow Jackets faithful and band aficionados, it is sweet music. They serenade us with Rocky Top and are our Band of the Week!More
  • UPDATE: Man killed while mowing grass when truck hit him; 3 teens inside truck also died

    UPDATE: Man killed while mowing grass when truck hit him; 3 teens inside truck also died

    Friday, August 29 2014 11:22 PM EDT2014-08-30 03:22:40 GMT
    4 teens inside truck that killed man on his lawn mower; Pinson only survivor4 teens inside truck that killed man on his lawn mower; Pinson only survivor
    Four teens were inside a vehicle that hit and killed 57-year-old Bryan Bartley while he was mowing grass on Thursday evening. Three teens also died in the tragedy. Alexis Pinson survived the crash and is improving, friends say. More
    Four teens were inside a vehicle that hit and killed 57-year-old Bryan Bartley while he was mowing grass on Thursday evening. Three teens also died in the tragedy. Alexis Pinson survived the crash and is improving, friends say. More
Powered by WorldNow
Can't find what you're looking for?

WRCB-TV
900 Whitehall Road
Chattanooga, TN 37405
(423) 267-5412

WRCB Jobs EEO | FCC Public Files

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WRCB. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.